Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to advertise during the big game. This hesitation could mean pharmaceutical ...